

Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application:

Listing of Claims:

- 1-10. (canceled)
11. (previously presented) A vector comprising a polynucleotide of claim 27.
12. (currently amended) A vector comprising a non-native expression control sequence operably linked to a polynucleotide selected from the group consisting of a polynucleotide of claim 27, ~~and~~ a polynucleotide of claim 30, and a polynucleotide of claim 32.
13. (currently amended) A host cell comprising a non-native expression control sequence operably linked to a polynucleotide selected from the group consisting of a polynucleotide of claim 27, ~~and~~ a polynucleotide of claim 30, and a polynucleotide of claim 32.
- 14-18. (canceled)
19. (currently amended) A method for producing an anthrax toxin receptor, the method comprising the steps of:
- transcribing a polynucleotide operably linked to an upstream expression control sequence, wherein the polynucleotide is selected from the group consisting of a polynucleotide of claim 27, ~~and~~ a polynucleotide of claim 30, and a polynucleotide of claim 32, to produce an mRNA; and
- translating the mRNA to produce the anthrax toxin receptor.
20. (original) A method as claimed in Claim 19, wherein the polynucleotide is operably linked to the expression control sequence in an expression vector, and wherein the expression vector is delivered into a host cell, the expression control sequence being operable in the host cell.
21. (original) A method as claimed in Claim 19, wherein at least one of the transcribing and translating steps are performed *in vitro*.
- 22-26. (canceled)

27. (currently amended) An isolated polynucleotide or complement thereof, the polynucleotide comprising a nucleotide sequence encoding an amino acid sequence ~~selected from the group consisting of SEQ ID NO:2, amino acids 27-321 of SEQ ID NO:2, and amino acids 28-320 of SEQ ID NO:2.~~

28. (currently amended) ~~An~~ The isolated polynucleotide or complement thereof, ~~of claim 27, wherein the polynucleotide consists of a nucleotide sequence that encodes encoding~~ an amino acid sequence selected from the group consisting of SEQ ID NO:2, amino acids 27-321 of SEQ ID NO:2, and amino acids 28-320 of SEQ ID NO:2.

29. (previously presented) The isolated polynucleotide of claim 27 comprising SEQ ID NO:1 from position 104 to 1207 or the complement thereof.

30. (previously presented) An isolated polynucleotide or complement thereof, the polynucleotide encoding an amino acid sequence selected from the group consisting of amino acids 41-227 of SEQ ID NO:2, amino acids 42-222 of SEQ ID NO:2, and amino acids 44-216 of SEQ ID NO:2.

31. (previously presented) The isolated polynucleotide of claim 30 wherein the polynucleotide encodes an amino acid sequence selected from the group consisting of amino acids 41-227 of SEQ ID NO:2 and amino acids 42-222 of SEQ ID NO:2.

32. (new) An isolated polynucleotide or complement thereof, the polynucleotide encoding a soluble polypeptide that comprises an amino acid sequence selected from the group consisting of amino acids 27-321 of SEQ ID NO:2 and amino acids 28-320 of SEQ ID NO:2.

33. (new) The isolated polynucleotide of claim 32, wherein the polynucleotide encodes a soluble polypeptide that comprises amino acids 27-321 of SEQ ID NO:2.

34. (new) The vector of claim 12, wherein the polynucleotide is selected from the group consisting of a polynucleotide of claim 27, a polynucleotide of claim 30, and a polynucleotide of claim 33.

35. (new) The host cell of claim 13, wherein the polynucleotide is selected from the group consisting of a polynucleotide of claim 27, a polynucleotide of claim 30, and a polynucleotide of claim 33.

36. (new) The method of claim 19, wherein the polynucleotide is selected from the group consisting of a polynucleotide of claim 27, a polynucleotide of claim 30, and a polynucleotide of claim 33.